{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:55:08Z","timestamp":1793282108543,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,20]]},"DOI":"10.1093\/infdis\/jiy428","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T18:19:18Z","timestamp":1531592358000},"page":"1773-1776","source":"Crossref","is-referenced-by-count":44,"title":["Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors"],"prefix":"10.1093","volume":"218","author":[{"given":"Wendy W","family":"Zhang","sequence":"first","affiliation":[{"name":"University of British Columbia, Vancouver, Canada"},{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K","family":"Cheung","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Oliveira","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie A","family":"Robbins","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Richard","family":"Harrigan","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniqa","family":"Shahid","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"key\n\t\t\t\t20181020040319187_CIT0001","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181020040319187_CIT0002","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181020040319187_CIT0003","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20181020040319187_CIT0004","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20181020040319187_CIT0005","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20181020040319187_CIT0006","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181020040319187_CIT0007","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1128\/AAC.03909-14","article-title":"Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection","volume":"59","author":"Yoshinaga","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181020040319187_CIT0008","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1128\/JVI.07133-11","article-title":"Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity","volume":"86","author":"Brockman","year":"2012","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20181020040319187_CIT0009","author":"Stanford University HIV Drug Resistance Database"},{"key":"key\n\t\t\t\t20181020040319187_CIT0010","doi-asserted-by":"crossref","first-page":"e46181","DOI":"10.1371\/journal.pone.0046181","article-title":"Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 \u201cdeep\u201d sequencing","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20181020040319187_CIT0011","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1128\/JVI.06618-11","article-title":"Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo","volume":"86","author":"Fransen","year":"2012","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20181020040319187_CIT0012","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","article-title":"Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro","volume":"52","author":"Malet","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181020040319187_CIT0013","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1128\/AAC.04844-14","article-title":"Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro","volume":"59","author":"Seki","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181020040319187_CIT0014","doi-asserted-by":"crossref","first-page":"e00315","DOI":"10.1128\/AAC.00315-17","article-title":"Impact of HIV-1 integrase L74F and V75I mutations in a clinical isolate on resistance to second-generation integrase strand transfer inhibitors","volume":"61","author":"Hachiya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181020040319187_CIT0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1021\/ci300541c","article-title":"Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis","volume":"53","author":"Xue","year":"2013","journal-title":"J Chem Inf Model"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/218\/11\/1773\/26120331\/jiy428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T16:31:11Z","timestamp":1661617871000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/218\/11\/1773\/5054084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,7,16]]},"published-print":{"date-parts":[[2018,10,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiy428","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12,1]]},"published":{"date-parts":[[2018,7,16]]}}}